Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash & Equivalents (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Cash & Equivalents for 4 consecutive years, with $40.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Cash & Equivalents rose 70.89% to $40.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $40.6 million, a 70.89% increase, with the full-year FY2024 number at $40.6 million, up 70.89% from a year prior.
  • Cash & Equivalents was $40.6 million for Q4 2024 at Lyra Therapeutics, up from $25.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $122.1 million in Q2 2022 to a low of $17.8 million in Q1 2024.
  • A 4-year average of $48.1 million and a median of $34.1 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 91.01% in 2022, then tumbled 76.35% in 2023.
  • Lyra Therapeutics' Cash & Equivalents stood at $46.1 million in 2021, then decreased by 26.33% to $33.9 million in 2022, then crashed by 30.04% to $23.7 million in 2023, then surged by 70.89% to $40.6 million in 2024.
  • Per Business Quant, the three most recent readings for LYRA's Cash & Equivalents are $40.6 million (Q4 2024), $25.8 million (Q3 2024), and $33.9 million (Q2 2024).